Evaluating the Off-Label Use of Omalizumab in Systemic Mastocytosis
A growing body of evidence suggests that omalizumab could be used to significantly alleviate symptoms associated with systemic mastocytosis.
SM Insights
The Challenges and Impact of Living With Systemic Mastocytosis
When clinicians speak about “health-related quality of life,” they are trying to quantify something that is quite unquantifiable; how can the grief upon receiving a life-altering diagnosis, or the burden of lifelong hospital visits, be justifiably measured? Nevertheless, efforts to understand the disease and treatment burden that a patient carries is a step in the…
Managing Systemic Mastocytosis in the Long Term
It is now more possible than ever for us to characterize the life experience of an individual with a chronic or incurable disease—understanding the complications that may arise along the way, when they may arise, and the best evidence-based methods to address them. In recent years, increased funding has flowed into research that stretches over…
ANCA Insights, HAE Insights, Insights, LAL-D Insights, LCFAOD Insights, MG Insights, MTC Insights, NMOSD Insights, Pompe Insights, SM Insights, WD Insights
Exploring the Parental Burden of Care of Children With Rare Diseases
The parental burden of care of children with rare diseases is considerable and deserves due attention and support.
The Unseen Disease Burden of Systemic Mastocytosis
In recent years, studies focusing on the impact of rare diseases on the quality of life of patients have proliferated; systemic mastocytosis (SM) is no exception. In Cancer, Mesa and colleagues write about the patient burden of SM based on results of the TouchStone Healthcare Provider Survey. Commenting on the state of medical literature surrounding…
Understanding Bone Pathology in Systemic Mastocytosis
Bone pathology is one of the more prominent features of systemic mastocytosis, often causing falls and fractures.
The Current Therapeutic Landscape for Systemic Mastocytosis
The therapeutic landscape for indolent/smoldering systemic mastocytosis and aggressive systemic mastocytosis is constantly evolving.
Diagnosing Gastrointestinal Disease in Patients With Systemic Mastocytosis
Gastrointestinal disease, such as diarrhea and abdominal pain, is a significant cause of morbidity in patients with systemic mastocytosis.
Tyrosine Kinase Inhibitors as a Therapeutic Option in Indolent Systemic Mastocytosis
Though no TKI is currently approved for the treatment of indolent SM (ISM), the most common variant of SM, several show great potential.
Therapeutic Strategies for Different Subtypes of Systemic Mastocytosis
Systemic mastocytosis is a disease with 5 different subtypes. Treating them remains a challenge for physicians today.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in SM Insights
Loading... 
Loading...